Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07072208 | Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL | recruiting | N/A | 43 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04704323 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 18 | Catapult TherapeuticsINDUSTRY | 2 | Jul 17, 2025 | clinicaltrials |
| NCT07070648 | Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET | recruiting | — | 300 | Fudan UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07051850 | Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies | recruiting | — | 174 | Sung-Soo ParkOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03807128 | MYeloma Resistance And Clonal Evolution(MYRACLE) | recruiting | — | 1,400 | Nantes University HospitalOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06682130 | Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL(ASCT DLBCL) | recruiting | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06976437 | A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors | recruiting | Early Phase 1 | 21 | YANRU WANGOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06871176 | PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05618041 | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | recruiting | N/A | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma(BAH2573) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07028970 | Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection | recruiting | — | 1,500 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06550427 | Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing | recruiting | — | 200 | National Taiwan University HospitalOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06700798 | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial | recruiting | Phase 2 | 90 | Fei LiOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | recruiting | Phase 4 | 59 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05219721 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 18 | Chunrui LiOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06940960 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05541341 | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | recruiting | — | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06717113 | A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma | recruiting | Early Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06793410 | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06999031 | A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04898647 | Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia(SLPRaresHvisc) | recruiting | N/A | 100 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06935162 | Teclistamab in Previously Treated AL Amyloidosis | recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06228794 | The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial | recruiting | — | 458 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT05759793 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT06890065 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06244368 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | recruiting | Phase 2 | 115 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971380 | Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis | recruiting | Phase 2 | 180 | Polina StepenskyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05294055 | Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma | recruiting | Phase 2 | 120 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05377307 | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | recruiting | — | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06959732 | Zanubrutinib Combined With G-CVP in Previously Untreated FL | recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT06699394 | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis | recruiting | N/A | 20 | Peking University People's HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05956457 | PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma | recruiting | N/A | 100 | Pack HealthINDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05635162 | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma(ZEBRA) | recruiting | Phase 2 | 50 | University College, LondonOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06140966 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03936153 | Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 170 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | recruiting | Phase 1 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT04300101 | Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)(MMCI) | recruiting | — | 300 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05945524 | Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination(ResisTec) | recruiting | N/A | 100 | University Hospital, ToulouseOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06250465 | AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry | recruiting | — | 500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05259553 | Biomarkers in Multiple Myeloma(VESICOM) | recruiting | N/A | 70 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06918912 | Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure(LORELY) | recruiting | Phase 2 | 50 | Istituto Clinico HumanitasOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05846880 | VitD3 Supplementation in Patients With Multiple Myeloma | recruiting | Early Phase 1 | 100 | Amany Keruakous, MD, MS.OTHER | 1 | Apr 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2025source: clinicaltrials